Elanco Animal Health (NYSE:ELAN) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Elanco Animal Health (NYSE:ELAN) issued its earnings results on Tuesday. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01), Zacks reports. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health’s quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.08 earnings per share.

Elanco Animal Health Stock Up 4.2 %

ELAN opened at $11.15 on Thursday. The business has a 50-day moving average of $11.74 and a 200-day moving average of $13.06. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health has a fifty-two week low of $10.20 and a fifty-two week high of $18.80. The company has a market capitalization of $5.51 billion, a PE ratio of 27.88, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of research analyst reports. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Barclays decreased their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday. Leerink Partners assumed coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective for the company. UBS Group decreased their price objective on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Stifel Nicolaus decreased their price objective on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $15.57.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.